Andrea De Giglio

20PUBLICATIONS
116CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

|Sep 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Alessio Cortellini, Valentina Santo, Leonardo Brunetti

|Aug 27, 2025
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

|Jun 13, 2025
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.

Sara Stumpo, Andrea Carlini, Francesco Mantuano

|Dec 05, 2024
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Alessandro Di Federico, Stefania Angelicola, Mariateresa Frascino

Pageof 4

Frequent Collaborators

14 joint publications

Alessandro Di Federico

9 joint publications

Francesco Gelsomino

4 joint publications

Biagio Ricciuti

4 joint publications

Francesca Sperandi